Treating HCV in HIV 2013: On the cusp of change

Liver International

Volumn 34, Issue SUPPL1, 2014, Pages 53-59

  Martel Laferrière, Valérie ^a   Dieterich, Douglas T ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Co infection; Direct acting antiviral agents; Hepatitis C; HIV

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DACLATASVIR; DIRECT ACTING ANTIVIRUS AGENT; FALDAPREVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ACUTE HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; MIXED INFECTION; NONHUMAN; REVIEW;

CO-INFECTION; DIRECT ACTING ANTIVIRAL AGENTS; HEPATITIS C; HIV;

ANTIVIRAL AGENTS; COINFECTION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; IMIDAZOLES; OLIGOPEPTIDES; PROLINE; THIAZOLES; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE;

EID: 84890864499     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12396     Document Type: Review

References (46)

1. Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007; 23: 972-82.
2. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
3. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-48.
4. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18: F27-36.
5. Soriano V, Maida I, Nunez M, et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antivir Ther 2004; 9: 987-92.
6. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50: 407-13.
7. Berenguer J, Rodriguez E, Miralles P, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis 2012; 55: 728-36.
8. Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int 2013; 33(Suppl. 1): 93-104.
9. Martel-Laferriere V, Brinkley S, Bichoupan K, et al. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med 2013; doi: 10.1111/hiv.12086. [Epub ahead of print].
10. Kirby B, Mathias A, Rossi S, et al. GS-7977 & HIV ARTs PK - no clinically significant pharmacokinetic interactions between sofosbuvir (GS-7977) and HIV antiretrovirals atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers. Hepatology 2012; 56(S1): 1067.
11. Garg V, Chandorkar G, Yang Y, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol 2013; 75: 431-9.
12. Kasserra C, Hughes E, Treitel M, Gupta S, O'Mara E. Clinical pharmacology of BOC: metabolism, excretion, and drug-drug interactions. 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, 27 February-2 March, 2011. (Abstract 118)
13. Bifano M, Hwang C, Oosterhuis B, et al. Assessment of HIV ARV drug interactions with the HCV NS5A replication complex inhibitor BMS-790052 demonstrates a pharmacokinetic profile which supports co-administration with tenofovir disoproxil fumarate, efavirenz, and atazanavir/ritonavir. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, 5-8 March, 2012.
14. Sabo JP, Kort J, Haschke M, et al. Pharmacokinetic interactions of darunavir/ritonavir, efavirenz, and tenofovir with the HCV protease inhibitor faldaprevir in healthy volunteers. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, 3-6 March, 2013.
15. Ouwerkerk-Mahadevan S, Sekar V, Peeters M, Beumont-Mauviel M. The pharmokinetic interactions of HCV protease inhibitor TMC435 with RPV, TDF, EFV, or RAL in health volunteers. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, 5-8 March, 2012. (Abstract 49)
16. Kakuda T, Leopold L, Nijs S, et al. Telaprevir and etravirine or rilpivirine. 13th HIV PK Workshop, Barcelona, 16-18 April, 2012. (Abstract O-18)
17. Rhee EG, Feng H-P, Xuan F, et al. Absence of a significant pharmacokinetic interaction between the HCV protease inhibitor boceprevir and HIV-1 NNRTI rilpivirine. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, 3-6 March, 2013. (Abstract 537)
18. Heeswijk RV, Garg V, Boogaerts G, et al. The pharmacokinetic interaction between telaprevir & raltegravir in healthy volunteers. 51st ICAAC, Chicago, 17-20 September, 2011. (Abstract A1-1738a)
19. Kanter CD, Blonk M, Colbers A, et al. The influence of the HCV protease inhibitor bocepravir on the pharmacokinetics of the HIV integrase inhibitor raltegravir. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, 5-8 March, 2012. (Abstract 772)
20. Heeswijk R V, Vandevoorde A, Boogaerts G, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, 27 February-2 March, 2011. (Abstract 119)
21. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13: 597-605.
22. FDA. Drug Safety Communication: important drug interactions between Vitrelis (boceprevir) and ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitor drugs. 2012. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm291119.htm. Accessed: 10 July 2013.
23. Bani-Sadr F, Carrat F, Rosenthal E, et al. Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment. Clin Infect Dis 2005; 41: 1806-9.
24. Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59: 434-41.
25. Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013; 144: 1450-55 e2.
26. Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51: 1122-6.
27. Dieterich D T, Rodriguez-Torres M, Sulkowski M S, et al. In APRICOT and PARADIGM 99% of HIV-HCV coinfected patients with an SVR12 achieved an SVR24 validating SVR12 as an endpoint for trials in this population. Hepatology 2012; 56(4 S1): 587A.
28. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159: 86-96.
29. Dieterich D, Rockstroh JK, Orkin C, et al. Simeprevir (TMC435) with peginterferon/ribavirin in patients co-infected with chronic genotype-1 HCV and HIV-1: week-24 interim analysis of the TMC435-C212 study. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, 3-6 March, 2013.
30. Dieterich D, Soriano V, Nelson M, et al. STARTVerso 4: high rates of early virologic response in HCV genotype 1/HIV-co-infected patients treated with faldaprevir plus pegIFN and RBV. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, 3-6 March, 2013.
31. ClinicalTrials.gov: a service of the U.S. National Institutes of Health. Available at http://www.clinicaltrials.gov. Accessed 4 September 2013.
32. Jacobson IM, Mchutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
33. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
34. Cachay ER, Wyles DL, Torriani FJ, et al. High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen. AIDS 2013; [Epub ahead of print].
35. Incivek (telaprevir) in combination with drugs peginterferon alfa and ribavirin (incivek combination treatment): drug safety communication - serious skin reactions. 2013. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm332860.htm. Accessed: 14 September 2013.
36. New drug application has been filed with FDA for simeprevir (TMC435) for combination treatment of adult patients with genotype 1 chronic hepatitis C. 2013. Available at http://www.medivir.se/v5/en/uptodate/pressrelease.cfm?year=2013&releaseid=758336. Accessed: 27 June 2013.
37. Fried MW, Buti M, Dore G J, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-29.
38. Sulkowski MS, Asselah T, Lalezari J, et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype1 HCV: SILEN-C1 trial. Hepatology 2013; 57: 2143-54.
39. Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-9.
40. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
41. Gilead Submits New Drug Application to U.S. FDA for sofosbuvir for the treatment of hepatitis C. 2013. Available at http://www.gilead.com/news/press-releases/2013/4/gilead-submits-new-drug-application-to-us-fda-for-sofosbuvir-for-the-treatment-of-hepatitis-c. Accessed: 10 June 2013.
42. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
43. European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 2011; 25: 399-409.
44. Obermeier M, Ingiliz P, Weitner L, et al. Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV): the "real-life setting" proves the concept. Eur J Med Res 2011; 16: 237-42.
45. Piroth L, Larsen C, Binquet C, et al. Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study. Hepatology 2010; 52: 1915-21.
46. Fierer D. Acute HCV infection - experiences from the United States. International Conference on Viral Hepatitis, New York, 25-6 March, 2012. (Plenary 5)